Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
about
Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependencyThe Bcl-2 apoptotic switch in cancer development and therapyThe BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cellsBH3 mimetics to improve cancer therapy; mechanisms and examplesRegulation of Bim in Health and DiseaseBcl-2 antagonists: a proof of concept for CLL therapyThe BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer TherapeuticsHow cell death shapes cancerBcl-x(L) blocks a mitochondrial inner membrane channel and prevents Ca2+ overload-mediated cell deathMechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosisGefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimeticsMulti-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemiaKnockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C ReleaseCyclic-AMP-dependent protein kinase A regulates apoptosis by stabilizing the BH3-only protein BimBIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutationsMET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agentsWhy do cancer cells become "addicted" to oncogenic epidermal growth factor receptor?Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancerERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapyHigh BIM mRNA levels are associated with longer survival in advanced gastric cancerBortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell lineDeletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose gamma-irradiation.Bcl2 is not required for the development and maintenance of leukemia stem cells in mice.Cell deathClinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1.Individual and overlapping roles of BH3-only proteins Bim and Bad in apoptosis of lymphocytes and platelets and in suppression of thymic lymphoma developmentPharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines.Cell metabolism: an essential link between cell growth and apoptosisSynergistic induction of cell death in liver tumor cells by TRAIL and chemotherapeutic drugs via the BH3-only proteins Bim and BidTyrosine kinase inhibitors: Multi-targeted or single-targeted?Imatinib spells BAD news for Bcr/abl-positive leukemiasThe essential role of evasion from cell death in cancer.
P2860
Q24315549-F2080064-5E69-4566-8522-4911824B6817Q24620437-230FF690-CF72-4442-BD48-B04BEA8C0CBEQ24650702-F72E1B40-90F0-422F-854C-76FD2F655267Q24655483-E37FEECA-F7BB-491C-89BF-6974C8B0A597Q26781203-3AE03086-C9B2-4DDB-8B2F-1BBEED9C38A8Q26823996-6A3DCAAB-BFAB-4D2F-91CE-14156B223E94Q27010154-B181DC56-2643-41BD-B492-F344D21ADB46Q27021441-08C3F86D-03BC-4C46-A4C8-5A03BBAA8A44Q27338716-0621AD06-E4E4-486C-8EC2-5F8F0C350272Q27851710-32AA2F78-F417-475A-9A39-2D4E2D70BFC5Q27851729-95A1723B-9F57-43FE-A385-8F4883013484Q28306984-890A45C6-F947-4FF0-8D42-4F705273A386Q28469345-D117F735-67B4-41C5-8753-ED9E235B94ECQ28541556-8D1159D0-EB76-406A-B7A9-C15312CFF574Q28550350-91CBA6F1-6411-4A85-965B-4E788C20FD1AQ28591851-9E23AFC4-7894-4F0E-92FE-5112E24C01C6Q28756824-F5550D83-432F-46A6-8555-2E68EB6027B1Q30502341-9FAB487B-9C8B-4802-BF34-4450DAFB1C5CQ33304557-37020370-4835-49F0-96EE-DBABEAADCC60Q33326515-95A9E28F-CDC9-4756-B7D6-BC117277D095Q33476874-1944A481-4F8D-4CFA-A9E6-51C4D7923FD0Q33598008-38EAB2EA-40B7-4F79-A7B5-E4A276B93B7FQ33747277-01698764-B7C5-4E84-A94A-CC7EEA1EF9F5Q33788708-EBF4D9DC-B851-4E9E-9992-85C8924FD9B7Q33797357-0DF5DACB-95FE-43BB-8B9A-476936A159E0Q33825096-CA6289EC-05BF-4499-8754-11628ED5109CQ33839818-CD7AF5FD-94EC-44E7-908E-8BF6291265D9Q33947776-AD517D64-424C-44BB-9FA5-226DC633125CQ34019760-9287CB69-2CA2-415D-9032-A902A26EADADQ34041761-C9B02C2B-BB12-4FD0-894B-2A7CCEC250B6Q34173253-5993ED1C-AED5-49CC-8119-BB08BC7EA455Q34184126-1BC3A041-47ED-4D77-854C-C6D9FCE7C490Q34192011-C04F38D4-E827-443E-92FD-6345B22B843BQ34221738-4EABAA26-5E50-4F52-AD1A-9F9C516D1A80Q34392064-377E4B9E-52A6-49FE-9DDD-F90F40467296Q34440592-D4C94B85-42F1-46EC-BCDB-66CA91370BE8Q34561806-46E45D97-7EE4-4441-A56A-C6BA11B970E8Q34983846-9A46EEDE-EA37-44C9-AD3D-4D59C887E5ABQ35075394-CF5F7861-AD3A-4527-BEAB-95A861C290DBQ35083049-22FF9CA5-439C-488B-8244-9A8304DF4523
P2860
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Bim and Bad mediate imatinib-i ...... is overcome by a BH3 mimetic.
@ast
Bim and Bad mediate imatinib-i ...... is overcome by a BH3 mimetic.
@en
type
label
Bim and Bad mediate imatinib-i ...... is overcome by a BH3 mimetic.
@ast
Bim and Bad mediate imatinib-i ...... is overcome by a BH3 mimetic.
@en
prefLabel
Bim and Bad mediate imatinib-i ...... is overcome by a BH3 mimetic.
@ast
Bim and Bad mediate imatinib-i ...... is overcome by a BH3 mimetic.
@en
P2093
P2860
P50
P356
P1476
Bim and Bad mediate imatinib-i ...... s is overcome by a BH3 mimetic
@en
P2093
Andreas Villunger
Junya Kuroda
Priscilla N Kelly
Shinya Kimura
P2860
P304
14907-14912
P356
10.1073/PNAS.0606176103
P407
P50
P577
2006-09-22T00:00:00Z